391 related articles for article (PubMed ID: 29868978)
1. RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
Lang JE; Ring A; Porras T; Kaur P; Forte VA; Mineyev N; Tripathy D; Press MF; Campo D
Ann Surg Oncol; 2018 Aug; 25(8):2261-2270. PubMed ID: 29868978
[TBL] [Abstract][Full Text] [Related]
2. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
4. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
[No Abstract] [Full Text] [Related]
5. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling of circulating tumor cells in metastatic breast cancer.
Lang JE; Scott JH; Wolf DM; Novak P; Punj V; Magbanua MJ; Zhu W; Mineyev N; Haqq CM; Crothers JR; Esserman LJ; Tripathy D; van 't Veer L; Park JW
Breast Cancer Res Treat; 2015 Jan; 149(1):121-31. PubMed ID: 25432738
[TBL] [Abstract][Full Text] [Related]
7. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
[TBL] [Abstract][Full Text] [Related]
8.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
9. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T;
ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
de Kruijff IE; Sieuwerts AM; Onstenk W; Jager A; Hamberg P; de Jongh FE; Smid M; Kraan J; Timmermans MA; Martens JWM; Sleijfer S
Int J Cancer; 2019 Aug; 145(4):1083-1089. PubMed ID: 30761532
[TBL] [Abstract][Full Text] [Related]
13. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers characterization of circulating tumour cells in breast cancer patients.
Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
[TBL] [Abstract][Full Text] [Related]
16. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
De Luca F; Rotunno G; Salvianti F; Galardi F; Pestrin M; Gabellini S; Simi L; Mancini I; Vannucchi AM; Pazzagli M; Di Leo A; Pinzani P
Oncotarget; 2016 May; 7(18):26107-19. PubMed ID: 27034166
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.
Onstenk W; Sieuwerts AM; Weekhout M; Mostert B; Reijm EA; van Deurzen CH; Bolt-de Vries JB; Peeters DJ; Hamberg P; Seynaeve C; Jager A; de Jongh FE; Smid M; Dirix LY; Kehrer DF; van Galen A; Ramirez-Moreno R; Kraan J; Van M; Gratama JW; Martens JW; Foekens JA; Sleijfer S
Cancer Lett; 2015 Jun; 362(1):36-44. PubMed ID: 25797316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
